ObsEva Closes CHF 60 Million in Series B Financing

On 23 November 2015, ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth, announced the closing of a CHF 60 million Series B preferred equity financing.

The closing was contingent on the execution of a strategic license and collaboration agreement between ObsEva and Kissei Pharmaceutical Co., Ltd. (a Japanese pharmaceutical company with approximately 70 years of history) related to the development and worldwide commercialization of KLH-2109/OBE2109 for the treatment of endometriosis and other potential indications.

Lenz & Staehelin acted as counsel to ObsEva. The team was led by Guy Vermeil (Corporate and M&A) and included associate Sevan Antreasyan (IP).